Celebrex plaintiff pool narrowed

U.S. District Judge Charles Breyer rules that plaintiffs "have not presented scientifically reliable evidence that Celebrex causes heart attacks or strokes when ingested at the 200 mg a day dose." A Nov. 19 decision will permit testimony on the 400 mg dose and whether Pfizer's COX-2 inhibitor is capable of causing strokes, noting that the latter question "is close." The case, In Re: Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, is pending in the Northern District of California...